ReviewMolecular and clinical oncology2025
Mechanism of the GALNT family proteins in regulating tumorigenesis and development of lung cancer (Review).
Review in Molecular and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Research progress in the role and mechanism of GALNT3 in human diseases (Review).Biomedical reports · 2026Review
- Proteomic signatures in cerebrospinal fluid and their clinical associations in patients with ME/CFS.Scientific reports · 2026Article
- GalNAc-Transferases in Cancer.Biomedicines · 2025Review
- Sex- and age- differences in the expression of critical blood-brain barrier regulators: a physiological context.Biology of sex differences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is one of the most common and lethal malignant tumors. Currently, surgical resection is the most effective treatment for early-stage lung cancer, and often results in favorable recovery outcomes. Therefore, early detection and control of lung cancer occurrence, invasion and metastasis are crucial for improving patient survival rates. Identifying tumor markers for lung cancer plays a vital role in facilitating early detection and control of its progression. The GALNT family proteins are enzymes that regulate the initial step in mucin O-glycan synthesis. It has been revealed that the expression of polypeptide N-acetyl-galactosamine-transferase (GALNT) family members is dysregulated in various tumors, and is closely associated with tumorigenesis, tumor cell growth, metastasis, adhesion, and serves as an important early indicator of tumor development. The present review compiles and analyzes findings concerning the role of GALNT family proteins in regulating lung cancer, with the goals of elucidating their mechanisms in lung cancer occurrence and progression and providing insights for improving the prognosis and therapeutic treatment of patients with lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.